

# Clinical research for the development of MASTL inhibitors as a new anti-cancer drug

Avelos Therapeutics, Inc.



ONCOLOGY	Phase 1
Product Type	Small molecule
Indication	Colorectal, Gastric, Sarcoma, TNBC, AML, etc.
Target	MASTL (Microtubule Associated Serine Threonine kinase Like)
MoA(Mechanism of Action)	Regulation of cell cycle (G2/M) and DNA damage response
Competitiveness	Competitors : Pfizer(Lead), OncordBio(Lead) Competitiveness - The first clinical stage of MASTL inhibitor in the world - Strong mono & combo efficacy in animal - 2 predictive biomarkers identified to maximize clinical success rates
Development Stage	Phase 1
Route of Administration	Oral

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*